Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

For Cancer Diagnosis, Precision Medicine Offers Better Alternative to Traditional Methods
  • USA - English


News provided by

JoTo PR

May 01, 2017, 12:00 ET

Share this article

Share toX

Share this article

Share toX

Paul Crowe, CEO of NuView Life Sciences, discusses the alternatives to traditional cancer diagnostics and the benefits of those alternatives.
Paul Crowe, CEO of NuView Life Sciences, discusses the alternatives to traditional cancer diagnostics and the benefits of those alternatives.

It’s time to focus on diagnostic tests that will accurately identify cancerous cells before any invasive procedures or surgeries are performed.

Post this

Park City, UT (PRWEB) May 01, 2017 -- Over the past two years, approximately 180,000 men were diagnosed with prostate cancer, and nearly 231,840 women were diagnosed with breast cancer.(1,2) Traditionally, invasive biopsies have been used to identify suspected cancers in most patients, but the rationale for biopsy is often based on flawed screening tests—such as prostate-specific antigen (PSA) and mammography—that often give false positive results. As the healthcare industry reexamines current diagnostic methods, NuView Life Sciences is working to develop a precision medicine-based diagnostic tool, NV-VPAC1, to accurately identify cancerous cells in patients long before biopsies are considered.

Unfortunately, it’s common for contemporary diagnostic screening tools, such as the PSA test or mammograms, to give false positive results. Almost half of all women who receive annual mammograms will experience a false positive test result,(3) and up to 80% of women who go on to have breast biopsies receive a benign diagnosis.(1,7) Nearly 70% of men who undergo biopsies for prostate cancer after receiving false positive PSA test results are shown to be cancer free.(1)

In both cases, false positive tests can result from other factors unrelated to cancer.(1,5) Many women have false positive mammograms due to their use of certain hormonal medications or the density of their breast tissue.(8) PSA test results can be elevated due to infection, certain drugs, obesity, or as the result of the normal aging process.(9)

Patients who receive false positive results often go on to have invasive tissue biopsies that are notoriously hard to interpret by trained medical professionals, making the entire biopsy process itself one that is prone to inaccurate results.(4) Regardless of the location of the suspected cancer, unwarranted biopsies increase a patient’s risk of infection, bleeding, and changes in appearance or function.(9,10)

Paul Crowe, CEO of NuView, says, “False positive cancer screenings can have devastating effects on patients and their families. They cost our healthcare system billions each year due to unnecessary biopsies and overtreatment. It’s time to focus on diagnostic tests that will accurately identify cancerous cells before any invasive procedures or surgeries are performed.”

Many patients undergo unnecessary treatments that result in severe emotional, physical and financial consequences as a result of false positive screening tests. Many women who receive inaccurate mammogram results experience further negative psychological consequences for as long as three years after initial testing.(5) Women who receive false positive results are also more likely to delay any subsequent mammograms, or even avoid them completely.(6)

To that end, NuView is working to develop its new NV-VPAC1 technology platform, which is able to hone in on VPAC1 receptors that are overexpressed on the surface of many types of cancerous cells. This new precision medicine-based diagnostic test is expected to offer accurate results that ensure a correct diagnosis without any need for invasive biopsies or other tests, especially for at-risk patients who have already had an elevated PSA test result or abnormal mammogram.

In the future, it may also be possible to use NuView’s NV-VPAC1 technology to accurately screen for prostate cancer after a positive PSA test result. The company is working towards using NV-VPAC1 as a screening tool for identifying cancerous cells. This will provide a more accurate, less expensive screening method for millions of men annually.

Crowe said, “A false positive screening result can have profoundly negative consequences for patients. If we can prevent a patient from undergoing invasive procedures that often result in pain and increased anxiety, then we’ve done our job well. We want to ensure that patients are able to receive accurate results in which they can be confident.”

About NuView Life Sciences:

Founded in 2005, NuView Life Sciences is a biotechnology company located in Park City, Utah, working to improve the way cancer is diagnosed and treated in our modern healthcare system. NuView is focused on creating precision cancer diagnostics and therapeutics to improve patient outcomes while reducing healthcare costs through the development and clinical application of its exclusive peptide analog technology, NV-VPAC1.

Led by a team of industry experts with decades of combined experience in healthcare and medical imaging technologies, NuView is poised to change how we look for and respond to cancer. To learn more about NuView Life Sciences, please visit http://nuviewinfo.com/site/3/.

Sources:
1. Experts reverse themselves on prostate cancer screenings. CNN. http://www.cnn.com/2017/04/11/health/prostate-cancer-screening-guidelines-draft/
2. Breast Cancer Facts & Figures, 2015 – 2016. American Cancer Society. https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/breast-cancer-facts-and-figures/breast-cancer-facts-and-figures-2015-2016.pdf
3. Limitations of Mammograms. American Cancer Society. https://www.cancer.org/cancer/breast-cancer/screening-tests-and-early-detection/mammograms/limitations-of-mammograms.html
4. Better Sent it to Epstein. Hopkins Medical News. http://www.hopkinsmedicine.org/hmn/F02/feature2.html
5. False Positives, False Negatives in Breast Cancer. Yahoo News. https://www.yahoo.com/news/false positives-false-negatives-breast-cancer-130000359.html
6. Impact of a False positive Screening Mammogram on Subsequent Screening Behavior and Stage at Breast Cancer Diagnosis. Cancer Epidemiology, Biomarkers & Prevention. http://cebp.aacrjournals.org/content/early/2017/02/06/1055-9965.EPI-16-0524
7. NV-VPAC1 Pet Imaging Agent. NuView Life Sciences. http://nuviewinfo.com/site/3/vpac1/
8. Accuracy of Mammograms. Susan G. Komen. http://ww5.komen.org/BreastCancer/AccuracyofMammograms.html
9. PSA test: Risks. Mayo Clinic. http://www.mayoclinic.org/tests-procedures/psa-testdetails/risks/cmc-20200313
10. Breast biopsy: Risks. Mayo Clinic. http://www.mayoclinic.org/tests-procedures/breast-biopsy/details/risks/cmc-20236110

Karla Jo Helms, JoTo PR, +1 (888) 202-4614 Ext: 802, [email protected]

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.